A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification
Sponsor: |
National Cancer Institute NCI |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS1468 |
U.S. Govt. ID: |
NCT03253679 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to determine if we can lower the chance of your cancer growing or spreading with the treatment of AZD1775. We want to find out if this approach is better or worse than the usual approach for your cancer with CCNE1 amplification. The usual approach is defined as care most people get for advanced cancer with CCNE1 amplification.
This study is closed
Investigator
Richard Carvajal, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have advanced solid tumors with a CCNE1 amplification? |
Yes |
No |
Have you had prior treatment with Wee1 kinase inhibition? |
Yes |
No |